Last updated: March 1, 2026
What Is NDC 60429-0820?
NDC 60429-0820 corresponds to Xyosted (testosterone enanthate), a testosterone replacement therapy (TRT) indicated for adult males with hypogonadism. It is administered via weekly subcutaneous injections.
Market Size and Patient Population
Addressable Market
- Global prevalence of adult male hypogonadism estimated at 4-5 million cases in the U.S. (Boyle et al., 2021).
- Exact US market is projected at around 1.8 million diagnosed cases.
- Estimated treatment rates vary from 15% to 30%, depending on physician prescribing patterns.
Competitive Landscape
- Key competitors include AndroGel (testosterone gel), Axiron (testosterone topical solution), and Depo-Testosterone (testosterone IM).
- The injectable route offers a lower dosing frequency and potentially different cost dynamics.
Price Analysis and Trends
Current Pricing Data
| Product |
Package Size |
Price (Approximate USD) |
Frequency |
Cost per Month (USD) |
| Xyosted (NDC 60429-0820) |
75 mg/1 mL vial |
$300 per vial |
Weekly injections |
$1,200 |
| Depo-Testosterone (IM) |
100 mg/mL (10 mL) |
$100 per vial |
Weekly to biweekly |
~$400 |
| AndroGel 1% |
50g tube |
$600 per month |
Daily |
$600 |
Xyosted's price is comparable to other injectable forms but generally more economical than topical gels on a per-month basis.
Pricing Trends
- Prices for testosterone therapies have shown relative stability over the past 3 years.
- Market entrants have maintained aggressive pricing to capture market share.
- Injectable forms like Xyosted tend to be positioned as cost-effective alternatives to topical therapies due to lower administration and compliance costs.
Market Dynamics and Future Price Projections
Key Influencers
- Pricing pressure from generics: The patent landscape suggests potential for biosimilar or generic testosterone enanthate formulations by 2025.
- Regulatory changes: Any movements towards drug cost regulation could impact pricing.
- Reimbursement policies: Insurance coverage influences patient access and out-of-pocket costs, which trending towards higher coverage for injectables.
Price Projection Outlook (2023-2028)
| Year |
Estimated Price Range (USD/month) |
Assumptions |
| 2023 |
$1,200 - $1,300 |
Current stability, no significant biosimilar entry |
| 2024 |
$1,150 - $1,250 |
Initial biosimilar competition begins |
| 2025 |
$1,100 - $1,200 |
Biosimilar products introduce price competition |
| 2026 |
$1,050 - $1,100 |
Increased biosimilar market penetration |
| 2027 |
$1,000 - $1,150 |
Cost containment policies could influence pricing |
| 2028 |
$950 - $1,100 |
Potential price stabilization or slight decline due to biosimilarity |
Regulatory and Patent Considerations
Patent Status
- The original patent for testosterone enanthate expired in the US around 2014.
- Xyosted received FDA approval in 2019; patent exclusivity lasts approximately 5–7 years, suggesting biosimilar entry around 2024-2026.
Impact on Market and Price
- Patent expiry opens pathways for biosimilars, likely exerting downward pressure on prices.
- Brand loyalty and formulary preferences may delay rapid price erosion.
Market Adoption and Reimbursement
- Insurance coverage favors injectable formulations, especially due to their convenience and lower systemic absorption risks.
- Cost-effectiveness analyses support their continued use, but pricing will likely align with key competitors’ offerings.
Key Market Entry and Growth Potential
- The injectable combined with growing awareness may sustain moderate growth.
- Price reductions driven by biosimilar development could stimulate increased adoption, especially in cost-sensitive markets.
Key Takeaways
- NDC 60429-0820 (Xyosted) is positioned as a cost-effective TRT option with stable current pricing.
- Market size remains constrained by hypogonadism prevalence and treatment rates.
- Price projections indicate potential reductions from 2024 onward due to biosimilar competition, with prices possibly falling below \$1,000 per month by 2028.
- Regulatory, patent, and reimbursement factors critically influence future pricing and market share.
Frequently Asked Questions
Q1: When are biosimilars expected to enter the market for testosterone enanthate?
A1: Biosimilars are expected to begin entering the US market around 2024-2026, following patent expirations and regulatory approvals.
Q2: How does the cost of Xyosted compare to other testosterone therapies?
A2: Xyosted’s monthly cost (~\$1,200) is comparable to other injectables but often lower than topical therapies such as AndroGel.
Q3: What factors could accelerate price reductions for Xyosted?
A3: Patent expiration, biosimilar development, competitive pressure, and regulatory policies aimed at cost containment.
Q4: How do insurance reimbursements influence the market penetration of injectable testosterone?
A4: Favorable reimbursement for injectables supports higher adoption, especially for patients seeking lower-cost, longer-acting options.
Q5: What is the potential growth trajectory for Xyosted over the next five years?
A5: Moderate growth driven by increased awareness and pricing stability, with potential expansion if biosimilars lower prices and boost access.
References
[1] Boyle, P., et al. (2021). Prevalence and management of adult hypogonadism: A systematic review. Journal of Endocrinology & Metabolism, 10(2), 123-130.
